Deals this week: Melinta Therapeutics, Cipher Pharmaceuticals, Baxter International
Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here
X

Deals this week: Melinta Therapeutics, Cipher Pharmaceuticals, Baxter International

12 Jan 2018

Melinta Therapeutics plans to raise $114.88m by issuing 6,920,714 shares of its common stock, priced at $16.6 a share.

Melinta Therapeutics plans to raise $114.88m by issuing 6,920,714 shares of its common stock, priced at $16.6 a share.

The US-based biopharmaceutical company has appointed Willkie Farr & Gallagher as the legal advisor for the transaction.

Cipher Pharmaceuticals has signed a distribution and supply agreement with Italmex Pharma (Italmex), which grants the latter exclusive rights to sell, commercialise and distribute the former’s Isotretinoin product in Mexico.

Manufacturing of Isotretinoin will be undertaken by Italmex’s partner, Galephar Pharmaceutical Research.

Cipher is a Canadian pharmaceutical company, while Italmex is also a pharmaceutical firm based in Mexico.

“Baxter International (Baxter) has signed an agreement with Mallinckrodt Plc to purchase the latter’s RECOTHROM Thrombin topical, and PREVELEAK surgical sealant for $185m.”

Baxter International (Baxter) has signed an agreement with Mallinckrodt to purchase the latter’s RECOTHROM Thrombin topical, and PREVELEAK surgical sealant for $185m.

Based in the US, Baxter is a medical products company, while Mallinckrodt is a biopharmaceutical company based in the UK.

The transaction will enable Baxter to broaden its haemostats and sealants portfolio.

Amryt Pharma has signed an agreement with RCC Pharma for the distribution of its Lojuxta (lomitapide) drug in Switzerland.

Lojuxta is indicated for the treatment of Homozygous Familial Hypercholesterolemia (HoFH).

Based in the UK, Amryt is a biopharmaceutical company, while RCC Pharma is a Switzerland-based pharmaceutical company.